Extended Data Fig. 3: Validation of results from high-throughput screening via luciferase mRNA delivery in non-pregnant mice.
From: Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia
LNP 6 (negative control), LNP 55 (placenta-tropic), LNP 97 (C12-200), and LNP 98 (DLin-MC3-DMA) were formulated with luciferase mRNA and administered to non-pregnant mice at a dose of 0.6 mg kg−1 mRNA. a, Six hours after administration, tissues (H: heart, Lu: lungs, Li: liver, K: kidneys, S: spleen) were dissected and imaged using an in vivo imaging system (IVIS). b–e, Luminescence was quantified in the (b) lungs, (c) liver, and (d) spleen which was then used to calculate (e) a spleen-to-liver ratio. Luminescence measurements are reported as the mean ± s.e.m. (n = 4 biological replicates). Ordinary two-sided, one-way ANOVAs with post hoc Student’s t tests using the Holm-Šídák correction for multiple comparisons were used to compare luminescence across treatment groups.
